COST-EFFECTIVENESS OF PNEUMOCOCCAL VACCINATION AMONG INFANTS IN RUSSIA- ECONOMIC EVALUATION OF THE PNEUMOCOCCAL 7-VALENT CONJUGATE VACCINE
Author(s)
Omelyanovsky VV1, Krysanov I2, Ivakhnenko O21Institute of Clinico-Economic Expertise and Pharmacoeconomics, RSMU, Moscow, Russia, 2Research Center for Clinical and Economic Evaluation and Pharmacoeconomics, Moscow, Russia
OBJECTIVES: Cost-effectiveness analysis of 4 dose (3+1) schedule of the conjugate pneumococcal 7-valent vaccine (PCV-7) in infants in the Russian Federation. METHODS: Costs associated with Streptococcus pneumoniae infection were calculated in a modeled cohort of children 0-5 years old with and without vaccination with PCV-7. Key parameters in the model included: number of children in the age of 0-5 years in the country; incidence of diseases caused by S. pneumoniae; the data about efficacy of PVC-7. Costs of vaccination, medical care costs and economic losses of a society were taken into account from the societal point of view. Time horizon was 5 years in the model. RESULTS: Expected cost of vaccination program is €0.469 million. Implementation of vaccination with PCV-7 will decrease direct medical costs of care for S. pneumoniae infection by €0.516 million. Societal economic losses will decrease by €0.975 million. Thus benefit amount of the PCV-7 vaccination program in a cohort of 0-5 years old children will be €1022 million. CONCLUSIONS: Vaccination with PCV-7 is an efficient program in Russia.
Conference/Value in Health Info
2010-11, ISPOR Europe 2010, Prague, Czech Republic
Value in Health, Vol. 13, No. 7 (November 2010)
Code
PIN40
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Infectious Disease (non-vaccine), Vaccines